Carrier cell-based delivery of replication-competent HSV-1 mutants enhances antitumor effect for ovarian cancer

Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma

(2009) Kah-Whye Peng et al.   AMERICAN JOURNAL OF HEMATOLOGY

Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes

(2009) Rumi Sasaki et al.   CARCINOGENESIS

Mesenchymal Stem Cell Carriers Protect Oncolytic Measles Viruses from Antibody Neutralization in an Orthotopic Ovarian Cancer Therapy Model

(2009) E. K. Mader et al.   CLINICAL CANCER RESEARCH

Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity

(2009) E J Ilett et al.   GENE THERAPY

Current status of gynecologic cancer in Japan

(2009) Kimio Ushijima   Journal of Gynecologic Oncology

Considerations for intravascular administration of oncolytic herpes virus for the treatment of multiple liver metastases

(2008) Naohiro Nomura et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy

(2008) A T Power et al.   GENE THERAPY

Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10

(2008) Daisuke Watanabe et al.   JOURNAL OF DERMATOLOGICAL SCIENCE